Ocular Therapeutix Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 1.79, this is below the company average, and notable indication of worsening business environment. Average receivable collection period, for the Ocular Therapeutix Inc in Mar 31 2026 quarter, has decreased to 204 days, compared to 205 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 506 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2026 from 2835 to 3272.

What is Receivable Turnover Ratio?
What is Ocular Therapeutix Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

OCUL Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	-3.47 %	-5.37 %	1.76 %	0.6 %	-4.99 %
Y / Y Revenue Change	0.81 %	-22.44 %	-5.71 %	-18.14 %	-27.59 %
Receivable Turnover Ratio (TTM)	1.79	1.78	1.88	1.92	2.02
OCUL's Total Ranking	# 3272	# 2835	# 1927	# 1787	# 2465
Accounts Receivable average collection period days	204	206	194	190	181
Seq. Receivable Change	-20.56 %	-0.38 %	1.17 %	20.58 %	-22.13 %
Seq. Revenue Change	-18.6 %	-8.9 %	8.06 %	25.81 %	-37.38 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 163
Healthcare Sector	# 507
Overall Market	# 3272

Receivable Turnover Ratio Statistics
High	Average	Low
9.22	4.44	1.78
(Mar 31 2016)		(Dec 31 2025)

OCUL Company Profile • Back to OCUL Efficiency Comparisons • Compare OCUL Receivables Turnover Ratio to its Competitors

Financial Statements
Ocular Therapeutix Inc 's Accounts Receivable	$ 24 Millions	Visit OCUL's Balance sheet
Ocular Therapeutix Inc 's Sales TTM	$ 52 Millions	Visit OCUL's Income Statement
Sources of OCUL's Revenues		Visit OCUL's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
OCUL's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
OCUL's Growth Rates	OCUL's Roa	OCUL's Inventory Turnover Ratio	OCUL's Dividend Comparisons
OCUL's Profitability Ratios	OCUL's Roi	OCUL's Asset Turnover Ratio	OCUL's Dividend Growth
OCUL's Valuation Ratios	OCUL's Roe	OCUL's Financial Strength Ratios	OCUL's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Conmed Corporation	5.86	$ 1,370.514 Millions	$ 233.896 Millions
Standard Biotools Inc	5.86	$ 85.215 Millions	$ 14.554 Millions
Arbutus Biopharma Corp	5.84	$ 191.445 Millions	$ 32.758 Millions
Editas Medicine Inc	5.84	$ 38.693 Millions	$ 6.622 Millions
Bioxcel Therapeutics Inc	5.84	$ 0.680 Millions	$ 0.117 Millions
Ardelyx inc	5.82	$ 427.679 Millions	$ 73.463 Millions
Resmed Inc	5.82	$ 5,504.590 Millions	$ 946.273 Millions
Illumina Inc	5.81	$ 4,393.000 Millions	$ 755.500 Millions
Prestige Consumer Healthcare Inc	5.81	$ 1,088.578 Millions	$ 187.445 Millions
Gossamer Bio Inc	5.80	$ 55.537 Millions	$ 9.575 Millions
Masimo Corp	5.80	$ 1,557.000 Millions	$ 268.525 Millions
Precision Optics Corporation Inc	5.80	$ 28.939 Millions	$ 4.994 Millions
Healthcare Services Group Inc	5.79	$ 1,852.277 Millions	$ 319.706 Millions
Caribou Biosciences Inc	5.79	$ 11.203 Millions	$ 1.936 Millions
Strata Critical Medical Inc	5.78	$ 209.937 Millions	$ 36.318 Millions
Integer Holdings Corporation	5.77	$ 1,854.663 Millions	$ 321.571 Millions
Mimedx Group Inc	5.76	$ 387.648 Millions	$ 67.289 Millions
Interpace Biosciences Inc	5.76	$ 35.664 Millions	$ 6.193 Millions
Nexalin Technology Inc	5.73	$ 0.276 Millions	$ 0.048 Millions
Mettler toledo International Inc	5.73	$ 4,089.782 Millions	$ 713.828 Millions
Edap Tms Sa	5.73	$ 112.115 Millions	$ 19.572 Millions
Zevra Therapeutics Inc	5.72	$ 115.073 Millions	$ 20.116 Millions
Ss Innovations International Inc	5.72	$ 48.259 Millions	$ 8.437 Millions
Elutia Inc	5.71	$ 14.984 Millions	$ 2.626 Millions
Surgery Partners Inc	5.70	$ 3,343.600 Millions	$ 587.000 Millions
Community Health Systems Inc	5.69	$ 12,291.000 Millions	$ 2,159.000 Millions
Bio rad Laboratories Inc	5.69	$ 2,589.300 Millions	$ 455.350 Millions
Jazz Pharmaceuticals Plc	5.64	$ 4,438.645 Millions	$ 786.354 Millions
Dentsply Sirona Inc	5.64	$ 3,681.000 Millions	$ 652.500 Millions
Medtronic Plc	5.64	$ 36,364.000 Millions	$ 6,452.500 Millions

Date modified: 2026-08-29T17:23:04+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.